Dominantly inherited alzheimer network: Facilitating research and clinical trials

Krista L. Moulder, B. Joy Snider, Susan L. Mills, Virginia D. Buckles, Anna M. Santacruz, Randall J. Bateman, John C. Morris

Research output: Contribution to journalReview articlepeer-review

102 Scopus citations

Abstract

The Dominantly Inherited Alzheimer Network (DIAN) is an international registry of individuals at risk for developing autosomal dominant Alzheimer's disease (AD). Its primary aims are to investigate the temporal ordering of AD pathophysiological changes that occur in asymptomatic mutation carriers and to identify those markers that herald the transition from cognitive normality to symptomatic AD. DIAN participants undergo longitudinal evaluations, including clinical and cognitive assessments and measurements of molecular and imaging AD biomarkers. This review details the unique attributes of DIAN as a model AD biomarker study and how it provides the infrastructure for innovative research projects, including clinical trials. The recent design and launch of the first anti-amyloid-beta secondary prevention trial in AD, led by the related DIAN Trials Unit, also are discussed.

Original languageEnglish
Article number48
JournalAlzheimer's Research and Therapy
Volume5
Issue number5
DOIs
StatePublished - 2013

Fingerprint

Dive into the research topics of 'Dominantly inherited alzheimer network: Facilitating research and clinical trials'. Together they form a unique fingerprint.

Cite this